Atom Therapeutics and China Medical System Holdings Sign Exclusive Deal for Lingdolinurad (ABP-671) to Treat Chronic Gout and Hyperuricemia

Atom Therapeutics Co. Ltd, a clinical stage biotechnology company hailing from Zhejiang, China, has announced a significant commercialization collaboration. The company has partnered exclusively with a subsidiary of China Medical System Holdings Ltd (CMS) to commercialize lingdolinurad (ABP-671), a novel oral medication designed to inhibit URAT1 and treat chronic gout and hyperuricemia. This partnership covers the territories of mainland China, Hong Kong SAR, and Macao SAR.

Lingdolinurad works by reducing the renal re-absorption of uric acid, and it has shown promise in multi-center Phase 2b/3 clinical trials conducted in both China and the United States. The drug has demonstrated safety and efficacy across various dose levels, ranging from 1 mg to 12 mg. Remarkably, a once-daily 2 mg dose of lingdolinurad is projected to be as effective as 80 mg of benzbromarone or febuxostat. The medication promises to offer a safer and more effective treatment for patients with chronic gout and hyperuricemia, maintaining its efficacy for over 24 hours without significant safety issues.

Through this agreement, Atom Therapeutics will benefit financially from substantial upfront and milestone payments from CMS. In return, Atom will pay fees for marketing and sales services to CMS. This collaboration is expected to generate significant revenue from the sales of lingdolinurad, marking a notable step forward in Atom Therapeutics' commercialization efforts for ABP-671.

CMS, known for its strong product lifecycle management and extensive experience in pharmaceutical innovation and commercialization, will play a crucial role in this partnership. By leveraging CMS's broad market channels and rich commercialization experience, Atom Therapeutics aims to swiftly promote and widely apply ABP-671 in clinical settings upon its release.

William Dongfang Shi, Ph.D., CEO, Chairman, and Founder of Atom Therapeutics, expressed enthusiasm about the collaboration, stating that it represents a profound integration of the two companies' business operations and strategic plans. He emphasized the goal of delivering more effective treatment options for patients with gout and hyperuricemia through this partnership as soon as possible.

Atom Therapeutics, originally named Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, officially adopted its new name on October 8, 2024. The company is a rapidly growing entity focused on developing best-in-class small molecule therapeutics for inflammatory and metabolic diseases. Lingdolinurad, its leading product, is in the late stages of clinical development for chronic gout treatment. Another promising small molecule, ABP-745, aimed at treating anti-inflammatory and autoimmune conditions, has completed Phase 1 clinical trials in the US, demonstrating favorable pharmacokinetics and safety, and is expected to enter Phase 2 trials soon.

CMS is recognized for its ability to bridge pharmaceutical innovation with commercialization, providing competitive products and services to address unmet medical needs. The company is committed to advancing the clinical research, development, and commercialization of innovative products, ultimately enhancing the translation of scientific research into clinical practice to benefit patients.

With a focus on several specialty therapeutic areas, CMS has established strong market positions for its major products through proven commercialization capabilities and extensive networks. The company continues to expand its business, particularly in the Southeast Asian market, aiming to serve as a gateway for global pharmaceutical firms entering this region. CMS's efforts include boosting the competitiveness of its cardio-cerebrovascular and gastroenterology business while independently operating its dermatology, medical aesthetics, and ophthalmology divisions.

This collaboration between Atom Therapeutics and CMS is poised to advance the commercialization of lingdolinurad, bringing a valuable new treatment option to patients suffering from chronic gout and hyperuricemia.